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Abstract
Purpose:  This  study  has  two  aims.  The  ﬁrst  is  to  compare  conventional  lipiodol  chemo-
embolization  (Trans  Arterial  Chemo-Embolization  —  TACE)  to  one  using  pre-loaded  particles
(Trans  Arterial  Chemo-Embolisation-Drug  Eluted  Bead  —  TACE-DEB)  using  a  cost  minimization
study.  The  second  is  to  deﬁne  the  fundable  nature  of  TACE-DEB  and  the  conditions  under  which
it  is  cost-effective.
Materials  and  methods:  Retrospective  study  of  patients  treated  by  chemo-embolization  (n  =  31:
TACE;  n  =  32:  TACE-DEB)  during  the  year  2010.  The  cost  minimization  study  was  conducted
from  the  hospital  perspective.  Direct  medical  costs  were  calculated  and  compared  using  the
readjusted  ENCC  (National  Studies  of  Costs  by  Common  Methodology)  method.  The  affordability
of  the  two  techniques  and  deﬁnition  of  a  cost-effective  hypothesis  (break-even  point)  were  also
established.
Results:  All  DRGs  combined,  lengths  of  stay  (TACE:  4.90  ±  3.36;  TACE-DEB:  5.03  ±  3.36)  does  not
change  signiﬁcantly.  An  average  upper  mean  cost  for  TACE-DEB  is  described  (TACE:  2869.05  D  ;
TACE-DEB:  3960.10  D  ).  The  affordability  calculations  in  the  study  show  that,  overall,  TACE-
DEB  can  be  funded  regardless  of  DRG.  A  ratio  of  1.3  procedures  using  the  conventional  (TACE)
method  would  enable  TACE-DEB  procedures  to  be  funded.
Conclusion:  This  medico-econom
able.
©  2013  Éditions  françaises  de  rad
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Liver  cancer,  or  hepatocellular  carcinoma  (HCC),  is  the
hird leading  cause  of  cancer  deaths  throughout  the  world
1]. It  is  the  ﬁfth  most  common  cancer  in  the  world  and  has
n estimated  incidence  of  approximately  700,000  new  cases
nnually [2].  Because  it  is  paucisymptomatic  resulting  in  late
iagnosis,  only  a  third  of  patients  suffering  from  HCC  are
ligible for  curative  treatment.  Clinicians  offer  palliative
are with  embolization  of  the  feeder  vessels  for  two-thirds
f inoperable,  non-metastatic  HCC  (Child  A-B,  intermediary
tage by  the  BCLC  [Barcelona  Clinic  Liver  Cancer]  classi-
cation [1,2].  Two  embolization  approaches  are  currently
vailable using  interventional  radiology  techniques.  The  ﬁrst
s based  on  the  principle  of  injecting  a  chemotherapy  emul-
iﬁed in  lipiodol  followed  by  vascular  embolization  with
esorbable particles.  This  is  the  conventional  technique  or
ACE (Trans  Arterial  Chemo-Embolization).  The  second  more
ecent technique  uses  non-resorbable  microspheres  loaded
ith cytotoxic  agents,  usually  doxorubicin.  These  are  car-
ied out  in  a  single  interventional  stage  and  are  commonly
alled TACE-DEB  (TACE-Drug  Eluting  Beads).
Both  techniques  have  been  shown  to  offer  similar  efﬁcacy
n terms  of  patient’s  length  of  survival  [3].  TACE-DEB  has
igniﬁcant technical  advances  as  it  does  not  require  extem-
oraneous preparation;  light  anesthesia  can  be  given  and
iver function  is  protected  by  targeted  chemo-embolization.
ccess to  this  latest  technique  in  healthcare  establishments
s currently  still  limited,  particularly  because  of  a lack  of
peciﬁc reimbursement  by  the  health  insurance  system.  The
conomic and  organizational  landscape  of  the  healthcare
ystem in  France  changed  greatly  in  2004  with  the  hospital
unding reforms  and  introduction  of  activity  based  tariffs
TAA) (law  no.  2003-1199  of  18  December  2003).  As  such,
ealthcare establishments  are  funded  by  their  activity  (type
nd volume  of  procedures)  by  amounts  linked  to  the  hospital
tays (SRG:  Stay  Reference  Group).  In  parallel,  and  in  order
o allow  access  to  expensive  new  medicinal  products  and
evices (MD),  a  list  of  reimbursable  products  in  addition  to
he SRG  was  introduced.  This  system  is  limited  in  terms  of
he time  delay  to  approve  new  procedures  and  devices,  par-
icularly new  technological  and  therapeutic  developments
uch as  the  TACE-DEB  technique.  The  cost  of  this  new  tech-
ique is  therefore  only  partially  covered  by  the  stay  tariff.
As  TACE-DEB  and  TACE  are  similarly  effective,  and  in  view
f the  technical  advantages  of  TACE-DEB  and  its  lack  of  reim-
ursement we  set  out  to  conduct  a  medico-economic  study
o support  healthcare  establishments  in  making  decisions.
We  have  carried  out  a  retrospective  medico-economic
ost minimization  analysis  to  establish  the  least  expensive
hemo-embolization technique  from  the  hospital’s  perspec-
ive [4].  The  cost  minimization  analysis  is  the  main  aim  of
his study.  In  parallel,  a  secondary  objective  was  to  establish
hether or  not  chemo-embolization  was  fundable  for  the
stablishment, based  on  a  affordability  analysis  and  mea-
urement of  the  break-even  point.
aterials and methodsatients
his  retrospective  study  was  carried  out  on  patients  suf-
ering from  inoperable,  non-metastatic  HCC.  The  patients
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eceived  a  course  of  hepatic  chemo-embolization  between
st January  2010  and  31st  December  2010  at  the  Nantes
niversity Hospitals,  either  TACE  (26  patients)  or  TACE-
EB (24  patients).  Each  course  received  by  the  patient  was
eemed to  be  a  new  procedure.  No  age  or  sex  criteria
ere included.  The  different  stages  of  the  liver  disease
ere deﬁned  according  to  the  Barcelona  classiﬁcation.
ost-hospital admission  consequences  were  not  included.
he doxorubicin-loaded  particles  used  were  DC-BeadsTM
Terumo,  Louvain,  Belgium)  and  the  (lipiodol)  embolization
articles used  for  the  TACE  were  either  resorbable  (Gelatins:
elitaspon or  GeliPuttyTM,  Gelita  Medical,  Estissac,  France)
r non-resorbable  (EmbogoldTM calibrated  particles,  Merit
edical, Voisins  le  Bretonneux,  France).
reatments
he  indication  for  TACE  or  TACE-DEB  was  decided  in  a
eekly multidisciplinary  meeting  attended  by  a  radiolo-
ist, a  surgeon,  a  gastroenterologist,  an  oncologist  and
 radiotherapist.  The  decisions  were  consistent  with  the
uidelines from  the  Barcelona  conference  [5]  and  the  TACE
nd TACE-DEB  procedures  were  carried  out  using  standard
rotocols in  the  Departments  of  Radiology.  In  both  treatment
ypes, the  angiographic  techniques  used  involved  catheter-
zation of  the  hepatic  artery  from  a femoral  approach  and
hen selective  catheterization  of  the  arterial  pedicles  feed-
ng the  tumors.  In  the  case  of  TACE,  this  was  followed
y infusion  of  an  emulsion  containing  10  mL  of  LipiodolTM
Guerbet,  France)  and  doxorubicin  (50—75  mg/m2)  followed
y embolization  with  hemostatic  gelatin  fragments  or
icrospheres, depending  on  angiographic  ﬁndings  and  the
perator’s usual  practice  until  ﬂow  stagnated  in  the  2nd  and
rd order  branches  of  the  hepatic  artery.  In  the  case  of  TACE-
EB, treatment  involved  an  injection  of  a  mixture  of  4  mL  of
C-BeadTM loaded  with  150  mg  of  doxorubicin  and  non-ionic
odinated contrast  medium.
ost minimization study
erspective
he  perspective  used  was  that  of  the  hospital,  counting
xpenditure related  to  the  length  of  stay  for  each  proce-
ure and  DRG  (Diagnostic  Reference  Group)  costs  according
o the  ENCC  (French  National  Scale  for  Common  Methodol-
gy Costs)  [6],  readjusted  for  the  actual  length  of  stay  in
he establishment.
easurement  of  costs
s  the  cost  minimization  study  was  retrospective,  we  con-
idered the  direct  medical  costs  which  were  analyzed  using
he readjusted  ENCC  method  [6].  Brieﬂy,  DRGs  are  used  to
stimate the  costs  from  PMSI  data  (Programme  to  Medicalise
nformation Systems)  and  from  ENCC.  Average  national  costs
re reprocessed  in  order  to  apply  to  the  establishment  in
hich the  study  is  being  carried  out.  Allocation  to  differ-
nt expenditure  lines  is  used  to  obtain  two  types  of  costs:
xed and  variable.  The  ﬁxed  costs  are  clinical  expenditure,
ogistics, and  general  administration  and  are  applied  on  a
aily basis  to  obtain  a  ﬁxed  daily  cost.  Variable  costs  do  not
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depend  on  length  of  stay  and  are  the  medical  and  technical
expenditure and  costs  directly  related  to  the  patient  [7].
The  DRG  categories  examined  in  this  study  were
‘‘malignant hepato-biliary  or  pancreatic  system  disorders’’
from level  1  (no  signiﬁcant  severity)  to  level  4  (major
severity) representing  the  severity  levels  from  each  of  the
patients. These  severity  levels  take  account  of  case  sever-
ity by  incorporating  associated  complications  or  morbidities.
Each DRG  has  a  tariff,  which  is  shown  in  Table  1.
Calculation  of  consumable  costs
All  of  the  IMD  and  other  consumables  required  for  the  proce-
dure were  recorded  and  their  costs  were  calculated  from  the
hospitals’ agreed  tender  prices.  A  microcosting  analysis  was
carried out  to  prepare  the  loaded  particles  in  the  UPCO  (Clin-
ical and  Oncology  Pharmacy  Unit).  This  method  was  used
to precisely  establish  the  resources  used  by  each  patient
in a  procedure:  surgical  time,  equipment  used,  laboratory
T
i
c
Table  1  List  of  DRG  linked  to  the  SRG  2010  tariffs  and  upper  
DRG  Wording  Payment
LEL* (D  )
07M061  Malignant,  hepato-biliary  or
pancreatic system  disorders,  level  1
07M062 Malignant,  hepato-biliary  or
pancreatic system  disorders,  level  2
07M063 Malignant,  hepato-biliary  or
pancreatic system  disorders,  level  3
1689.70 
07M064 Malignant,  hepato-biliary  or
pancreatic system  disorders,  level  4
3411.61 
Extract from the Ofﬁcial Journal of the Republic of France dated 28 Fe
*Lower exemption limit; **upper exemption limit.
Table  2  Description  of  medical  devices  used  depending  on  th
Type  of  embolization  TACE  conv.  
Materials  U.P.
Tax
Embolization  agents
or IMD
1 Geli-Putty® hemostatic
gelatin unit
24.1
Or Or  
1 bottle  of  embolization
microspheres  CeloNova
124
Other consumables  1  TERUMO  Angled  0.032  guide  15.0
1 Cobra  Small  5F  catheter  10.6
1 TERUMO  5F  short  introducer  13.0
1 2-way  HP  tap 3.00
1 Progreat  2.7  TERUMO*
micro-catheter
335
TOTAL 400
524
Unit price (U.P.). Excluding tax (ex. tax) extracted from the establishm
*Quasi-routine use.y  429
nvestigations  and  imaging,  etc.  Calculation  of  resources  the
esources consumed  was  used  to  establish  the  actual  costs
ttributable to  the  different  strategies  (Table  2).
alculation  of  establishment  hospitalization  costs
he  DRG  representing  the  different  stays  chosen  were  pro-
ided by  the  Nantes  University  Hospital  Medical  Information
epartment (DIM).  The  related  lengths  of  stay  were  recov-
red from  the  Nantes  University  Hospitals  with  ClinicomTM
oftware  (Intersystems  France,  Paris,  France).  The  ﬁxed
nd variable  costs  were  weighted  by  DRG  and  length
f stay.
RG  reimbursement
he  Nantes  University  Hospital  DIM  searched  for  the  theoret-
cal and  actual  SRG  reimbursement  rates  for  each  procedure
arried out  during  the  study  period.
and  lower  limits.
Lower
limit
Stay payment
2010  (D  )
Upper
limit
Tariff
UEL** (D  )
2505.15  9  127.83
4939.84  28  153.61
5  6623.55  39  189.53
10  10035.16  57  327.33
bruary 2010.
e  type  of  embolization.
TACE-DEB
 ex.
 (D  )
Materials  U.P.  ex.
Tax (D  )
1 1  bottle  of  DC-BeadTM
loadable  microspheres
720.00
Or  Or
.17 2  bottles  of  DC-BeadTM
loadable  microspheres
1440.00
0  1  TERUMO  Angled  0.035  guide  15.00
5  1  middle  5F  Cobra  catheter  10.65
0  1  TERUMO  5F  short  introducer  13.00
 1  3-way  HP  tap  3.00
.00  1  Progreat  2.7  TERUMO
microcatheter
335.00
.76  to
.93
1,096.65
to  1816.65
ents tendering database.
4A
A
u
A
v
C
T
c
t
T
C
A
m
A
A
T
T
p
T
R
P
T
r
m
t
n
y
P
F
0
o
•
•
•
•
L
T
l
w
r
C
T
c
(
T
2
t
a
c
r
t
w
r
D
p
A
T
o
c
o
0
W
h
(
n
c
a
T
compared to  13%  for  TACE-DEB  technique.  On  the  other
hand, affordability  is  particularly  negative  for  TACE-DEB,
47% of  procedures  result  in  a  loss  of  over  1000  D  compared30  
ffordability  study
ffordability  calculation:  cost  effectiveness  was  calculated
sing the  following  equation:
ffordability  =  SRG  payment  −  Total  cost  of  stay
The  total  cost  of  the  stay  was  the  sum  of  the  ﬁxed  and
ariable costs.
alculation  theoretical  affordability
heoretical  affordability  was  calculated  from  the  theoreti-
al SRG  payments  set  by  the  Decree  of  27  February  2010  for
he year  2010  according  to  the  following  equation  [6]:
heoretical  affordability  =  Theoretical  SRG  2010  payment
− Total  costs  of  stay
alculation  of  actual  affordability
ctual  affordability  was  calculated  from  the  actual  pay-
ents obtained  from  the  DIM.
ctual  affordability = Actual  payment −  Total  cost  of  stay
ffordability  break-even  point
he  hypothesis  used  was  based  on  deﬁning  a  number  of
ACE procedures  which  could  be  performed  in  order  to  com-
ensate for  the  average  deﬁcit  due  to  a  less  cost-effective
ACE-DEB procedure.
esults
opulation
hirty-one  conventional  TACE  and  32  TACE-DEB  courses  were
ecorded  in  2010.
Forty-nine of  the  procedures  included  or  carried  out  in
en and  14  in  women.  The  sex  ratio  was  uneven  with  3.5
imes more  men  than  women  treated.  This  is  consistent  with
ational epidemiological  ﬁndings.  The  average  age  was  65
ears old.
atient distribution by DRG
our  DRG  were  involved  (07M061,  07M062,  07M063,
7M064). The  distribution  of  patients  who  underwent  TACE
r TACE  DEB  according  to  the  different  DRG  is  shown  below:
DRG 07M061:  20  TACE,  26  TACE-DEB;
DRG 07M062:  6  TACE,  4  TACE-DEB;
DRG 07M063:  5  TACE,  1  TACE-DEB;
DRG 07M064:  1  TACE-DEB.
ength of hospitalizationhe  average  lengths  of  hospitalization  for  each  DRG  are
isted in  Table  3.  When  all  of  the  DRGs  were  combined,  there
ere no  signiﬁcant  differences  between  the  lengths  of  stay
egardless  of  chemo-embolization  technique  used.
F
e
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ost minimization analysis
he  average  total  stay  costs  were  used  to  make  a  ﬁnan-
ial comparison  of  the  two  types  of  chemo-embolization
Table 3).
When all  of  the  DRG  combined,  the  average  cost  of  a
ACE-DEB chemo-embolization  was  3960.10  D  compared  to
869.05 D  for  a  TACE.  This  therefore  represents  an  addi-
ional cost  of  1091.05  D  .
The embolization  agents  were  responsible  for  the  major
dditional cost  of  the  difference  between  the  average  stay
osts. The  doxorubicin  loaded  embolization  particles  were
esponsible for  an  additional  cost  of  879.44  D  .  These  par-
icles alone  therefore  made  up  25%  of  the  total  stay  cost
hereas the  IMD  for  lipiodol  chemo-embolization  only  rep-
esented 2%  of  the  total  stay  cost.
The  average  cost  of  the  other  consumables  for  the  TACE-
EB procedure  was  77.20  D  more  than  the  cost  of  a  TACE
rocedure.
ffordability study
he  ﬁrst  comparison  of  theoretical  affordability  was  carried
ut before  considering  actual  affordability.
The  sum  of  the  theoretical  affordability  for  each  of  the
hemo-embolizations by  DRG  is  shown  in  Fig.  1.  Regardless
f embolization  type,  the  theoretical  SRG  tariff  for  DRG
7M061 does  not  cover  the  cost  of  chemo-embolization.
hen the  stay  is  included  in  DRGs  07M062  and  07M063,
owever, the  conventional  chemo-embolization  technique
TACE) becomes  cost-effective  whereas  the  TACE-DEB  tech-
ique remains  in  deﬁcit.  The  TACE-DEB  technique  is  only
ost-effective when  DRG  07M064  is  used.
Analysis  of  the  distribution  of  procedures  by  theoretical
ffordability and  (Fig.  2)  shows  ﬁrstly  that  the  conventional
ACE technique  is  generally  cost-effective  in  64%  of  cases,igure 1. Theoretical affordability of TACE and TACE-DEB
mbolization techniques. Theoretical affordabilities were calcu-
ated  for each DRG depending on the embolization technique
Materials and methods).
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Table  3 Comparison  of  lengths  of  stay  and  all  mean  costs  between  conventional  TACE  and  TACE-DEB.
DRG  TACE  conv. TACE-DEB
Mean  length  of
stay DMS  (d)
Mean cost
of stay  (D  )
Mean cost.
IMD (D  )
Mean cost  of
consumables  (D  )
Mean  length  of
stay (d)
Mean  cost
of stay  (D  )
Mean cost
of IMD  (D  )
Mean cost  of
consumables  (D  )
07M061  4.30  2801.24 86.01 365.02 4.23 3685.97 904.85 465.49
07M062  4.33  2436.38 13.52 408.91 9.25 5388.70 1102.39 390.80
07M063  8.00  3659.52 27.87 300.79 9.00 5628.41 1475.67 393.70
07M064  5.00  3704.79  734.10  98.55
Mean  of  SRG
and costs
4.90 ±  3.36  2869.05  62.60  365.24  5.03  ±  3.36  3960.10  942.04  442.44
Mean Length of Stay (DMS) and mean costs are expressed for each of the Diagnostic Reference Groups (DRG) included in this study. Lengths of stay were extracted from the healthcare
software (Clinicom). The average cost of stay was assessed using the readjusted ENCC method. IMD and the consumable costs were determined by microcosting of reconstitution of the
chemo-embolization particles. The mean of the DMS and the mean of the costs for all DRG by embolization technique were also calculated.
432  J.  Clouet  et  al.
Figure 2. Theoretical affordability was obtained by subtracting
the  SRG (set by the decree of 27 February 2010) from the actual
calculated costs for each stay in the establishment. Affordability
is  expressed in 500-euro bands. The TACE technique remains the-
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Figure 4. Distribution in percentages of procedures by actual
affordability bands and type of embolization. Actual affordabil-
ity  was calculated by subtracting the actual payments obtained
from  the establishment’s Medical Information Department from the
actual  hospitalization cost. Affordability levels are expressed in 500
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pretically  cost-effective in 64% of cases compared to 12% of the
ACE-DEB  technique.
o  9%  of  TACE  procedures.  Therefore  eighty-seven  per  cent
f TACE-DEB  chemo-embolization  produce  a  deﬁcit.
The  actual  payments  may  differ  from  the  theoretical  SRG
ayments, particularly  when  expensive  compounds  (doxoru-
icin) or  IMD  which  are  additionally  reimbursed  are  required
none in  this  situation).  These  payments  can  also  be  inﬂu-
nced by  the  patient  reimbursement  rates.  Data  on  actual
ffordability are  shown  in  Figs.  3  and  4.
Unlike  the  theoretical  affordability  assessment,  actual
ffordability can  show  whether  the  conventional  technique
s fundable  regardless  of  the  DRG,  including  DRG07M061
Fig. 3).  Overall,  the  TACE-DEB  technique  is  also  fundable
egardless of  DRG  (Fig.  3).
An  analysis  of  the  distribution  of  procedures  by  positive
r negative  affordability  (Fig.  4)  over  the  study  period  shows
hat almost  all  of  the  conventional  procedures  are  fundable
97%). Only  one  stay  was  found  to  have  negative  affordability
f 0  to  −500  D  which  is  explained  by  high  use  of  concomitant
igure 3. Actual affordability by type of embolization and DRG.
verall,  actual affordability shows that the conventional techniques
nd  the TACE-DEB techniques are fundable regardless of DRG.
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auro bands. The sum of the affordabilities for the 63 patients in the
tudy  remains positive, including for the TACE-DEB technique.
D  as  the  patient  underwent  parallel  radio-frequency  abla-
ion in  parts  of  the  tumor  (Fig.  4).
In  terms  of  the  TACE-DEB  procedures,  we  can  consider
hat half  of  these  are  fundable.  Actual  affordability  of
ver 0  D  is  seen  for  50%  of  patients  treated  with  TACE-DEB
Fig. 4).
ffordability breakeven point
n  order  to  be  cost-effective,  an  average  of  at  least  1.3
imes more  conventional  TACE  procedures  needs  to  be  per-
ormed than  TACE-DEB.  In  reality  in  2010,  75  conventional
ACE procedures  and  33  TACE-DEB  procedures  were  carried
ut, i.e.  2.3  times  more  conventional  TACE  than  TACE-DEB
rocedures, which  leads  us  to  assume  that  the  establishment
roﬁted from  the  chemo-embolizations  carried  out  in  2010.
iscussion
he  chemo-embolization  techniques  proposed  recently
o treat  patients  suffering  from  non-metastatic,  inop-
rable HCC  are  new  techniques  whose  ﬁnancial  impact
n healthcare  establishments  is  poorly  understood.  The
nly randomized  phase  II  study  (PRECISION  V  study)  which
as been  published  to  date  comparing  patients  treated
ith conventional  chemo-embolization  (TACE)  or  chemo-
mbolization with  loaded  microspheres  (TACE-DEB)  showed
o signiﬁcant  difference  between  the  2  procedures  in  terms
f 6  month  efﬁcacy  [3]  The  medico-economic  analysis,
nd particularly  a  cost  minimization  analysis,  therefore
ppeared to  be  a  useful  tool  for  healthcare  establishments  in
eciding on  their  strategic  choices  [4].  From  this,  our  study
as shown  that  a  ratio  of  1.3  procedures  using  the  conven-
ional method  (TACE)  should  allow  TACE-DEB  procedures  to
e funded.
Our analysis  of  economic  data  showed  a  signiﬁcantly
igher additional  stay  cost  for  TACE-DEB  compared  to
 conventional  TACE  stay  (average  1091.05  D  ).  These
 stud
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differences  are  explained  by  two  main  expenditure  lines:
ﬁrstly expenditure  due  to  other  consumables  including  non-
implantable  MD  used  during  the  embolization  technique
(catheter, guide,  probe,  micro-catheter).  Micro-catheters
(335.00 D  per  unit  excluding  tax.)  are  used  almost  routinely
in TACE-DEB  chemo-embolization  whereas  this  is  not  the
case with  the  TACE  procedure.  The  second  cost  plan  explain-
ing the  differences  are  the  IMD  made  up  of  the  embolization
agents.
A comparison  of  actual  and  theoretical  affordability
shows that  actual  payments  are  on  average  1.5  times  greater
than theoretical  payments,  therefore  reducing  the  addi-
tional cost  and  increasing  affordability.  These  differences
can be  explained  by  use  of  expensive  molecules  during
the stay,  which  require  additional  reimbursement  (partic-
ularly doxorubicin).  These  costs  are  incorporated  into  the
actual payments  by  the  Nantes  University  Hospitals  conver-
gence rate  and  by  patient  reimbursement  rates  given  by  the
National Health  Insurance  Funds.
The  theoretical  payments  were  used  in  the  subsequent
assessment of  loaded  particles  in  order  to  be  able  to  remove
bias, particularly  from  differential  patient  reimbursement
rates.
The theoretical  affordability  studies  showed  that  only
13% of  TACE-DEB  procedures  are  cost-effective  compared
to 64%  for  conventional  procedures.  In  order  to  examine
how loaded  microspheres  could  be  fundable,  a  break-even
affordability hypothesis  was  put  forth.  The  two  techniques
for the  procedures  become  fundable  when  they  are  used
together in  the  ratio  of  1.3  conventional  TACE  procedures
to each  TACE-DEB  procedure.  This  involves  patient  selec-
tion and  selection  of  disease  severity  so  that  its  activity  can
be  funded  by  the  health  care  establishment.
This  retrospective  study  has  showed  that  the  use  of
loaded particles  has  a  genuine  ﬁnancial  impact  although
the limitations  of  the  study  sample  need  to  be  considered.
The study  population  was  not  matched,  which  reduces  the
power of  the  statistical  tests,  and  in  addition,  low  patient
recruitment in  the  DRG  of  patients  with  high  co-morbidities
(DRG 07M063  and  DRG  07M064)  in  the  conventional  TACE
group makes  it  difﬁcult  to  interpret  and  compare  the  two
types of  embolization.  The  cost  minimization  analysis  which
was carried  out,  however,  does  show  an  additional  cost  of
chemo-embolization with  loaded  particles  to  treat  HCC  in
the establishment  over  the  year  2010.  These  results  are
consistent with  those  of  another  study  which  showed  a  sig-
niﬁcantly higher  annual  cost  for  TACE-DEB  [8].  Another  study
has shown  a  lower  overall  cost  for  chemo-embolizations  car-
ried out  using  HepaSphereTM loaded  microspheres  (Biosphere
Medical, South  Jordan,  USA)  compared  to  conventional
chemo-embolization.  [9].  This  reduction  in  cost  was  mostly
due to  the  lower  intrinsic  cost  of  the  HepaSphereTM com-
pared to  the  DC-BeadTM used  in  our  study.  This  study  also
only considered  the  ﬁrst  course  of  chemo-embolization  and
not all  of  the  courses  received  by  the  patients  suffering
from HCC.  In  addition,  patients  recruited  for  chemo-
embolization with  HepaSphereTM had  uni-  or  paucifocal  HCC
and multifocal  or  diffuse  HCC  was  treated  with  conven-
tional chemo-embolization.  These  were  therefore  patients
suffering from  less  severe  HCC  who  were  selected  to  receive
chemo-embolization with  HepaSphereTM.  Finally,  this  study
was based  on  two  different  versions  of  the  DRG  classiﬁcationy  433
versions  10C  and  v11)  which  had  fewer  severity  levels  in  the
0C version  and  resulted  in  a  shift  of  patient  classiﬁcation,
owards severer  co-morbidities  which  were  therefore  better
emunerated. Four  levels  of  severity  are  listed  in  the  current
ersion. The  reimbursement  of  patients  with  co-morbidities
s ﬁnancially  lower  (level  1  or  2)  [10].  A  study  by  the  same
roup has  recently  been  published  [11]  which  examined  the
osts of  TACE-DEB.  The  cost  results  from  our  study  partially
onﬁrm those  reported  in  this  study.  The  study  did  not,  how-
ver, support  the  potential  self-funding  of  TACE-DEB  by  TACE
s we  have  shown,  particularly  for  some  DRGs.
In  addition  to  this  cost  analysis,  this  work  shows  that  it  is
ossible to  fund  the  DC-BeadTM for  DRG  07M064.  Along  the
ame lines  as  the  studies  discussed  above  [9,11],  it  would
robably be  useful  to  continue  investigations  with  particu-
ar emphasis  on  this  DRG.  As  the  Precision  V  study  [3]  showed
hat DC-BeadTM laden  particles  offered  a  clinical  beneﬁt  to
atients suffering  from  advanced  HCC  this  new  approach
ould be  particularly  interesting.  Future  studies  would  also
eed to  take  into  account  the  anesthetic  resources  which
re more  limited  with  the  TACE-DEB  technique,  though  this
s only  rarely  considered,  and  also  take  account  of  the  fact
hat patient  tolerability  is  better  for  TACE-DEB  than  it  is  for
he TACE  technique.
onclusion
his  study  highlights  the  difference  which  may  exist  between
stimated hospital  costs  and  the  corresponding  reimburse-
ent amount  for  the  hospital  stay.  This  shows  sustainable
ccess to  new  surgical  developments  for  each  patient  in
 context  of  hospital  deﬁcit  reduction  and  the  desire
or convergence  between  private  and  public  healthcare
stablishments. This  study  has  demonstrated  that  TACE-
EB procedures  can  be  funded  with  a  ratio  of  1.3  to  1
TACE/TACE-DEB).
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